Business, energy, technology, markets and global industry news from Business News Today

oncology biosimilars

PharmaDeviceNews oncology biosimilars
Representative image: Samsung Bioepis’ SB27 Keytruda biosimilar trial results highlight a potentially important step toward lower-cost pembrolizumab competition in the global oncology market.
Pharma & Biotech

Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates

Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.

Read More
Pharma & Biotech

Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?

Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.

Read More